{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T11:20:32Z","timestamp":1775042432685,"version":"3.50.1"},"reference-count":46,"publisher":"Hindawi Limited","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":623,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Takeda Pharmaceutical Company, Ltd"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1111\/ijcp.12328","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T09:54:23Z","timestamp":1387274063000},"page":"49-59","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder"],"prefix":"10.1155","volume":"68","author":[{"given":"A. R.","family":"Mahableshwarkar","sequence":"first","affiliation":[{"name":"Takeda Development Center Americas; Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. L.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas; Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Chen","sequence":"additional","affiliation":[{"name":"Takeda Development Center Americas; Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"Simon","sequence":"additional","affiliation":[{"name":"Northbrooke Research Center; Brown Deer WI USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,12,17]]},"reference":[{"key":"10.1111\/ijcp.12328-BIB0001|ijcp12328-cit-0001","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int J Methods Psychiatr Res"},{"key":"10.1111\/ijcp.12328-BIB0002|ijcp12328-cit-0002","article-title":"Impairment and functioning in a sample of primary care patients with generalized anxiety disorder: results from the primary care anxiety project","volume":"12","author":"Weisberg","year":"2010","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0003|ijcp12328-cit-0003","first-page":"35","article-title":"Generalized anxiety disorder in primary care: emerging issues in management and treatment","volume":"63","author":"Culpepper","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0004|ijcp12328-cit-0004","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/da.20257","article-title":"Human and economic burden of generalized anxiety disorder","volume":"25","author":"Hoffman","year":"2008","journal-title":"Depress Anxiety"},{"key":"10.1111\/ijcp.12328-BIB0005|ijcp12328-cit-0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0006|ijcp12328-cit-0006","first-page":"51s","article-title":"Clinical practice guidelines: management of anxiety disorders","volume":"51","author":"Swinson","year":"2006","journal-title":"Can J Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0007|ijcp12328-cit-0007","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/S1461145710001434","article-title":"Evidence-based pharmacological treatment of generalized anxiety disorder","volume":"14","author":"Baldwin","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0008|ijcp12328-cit-0008","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/PPA.S4633","article-title":"Predictors of premature discontinuation of treatment in multiple disease states","volume":"3","author":"Nantz","year":"2009","journal-title":"Patient Prefer Adherence"},{"key":"10.1111\/ijcp.12328-BIB0009|ijcp12328-cit-0009","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton","year":"1959","journal-title":"Br J Med Psychol"},{"key":"10.1111\/ijcp.12328-BIB0010|ijcp12328-cit-0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0011|ijcp12328-cit-0011","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1744-859X-10-7","article-title":"Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?","volume":"10","author":"Bobes","year":"2011","journal-title":"Ann Gen Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0012|ijcp12328-cit-0012","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.neulet.2011.09.058","article-title":"5HT(1A) and 5HT(1B) receptors of medial prefrontal cortex modulate anxiogenic-like behaviors in rats","volume":"504","author":"Solati","year":"2011","journal-title":"Neurosci Lett"},{"key":"10.1111\/ijcp.12328-BIB0013|ijcp12328-cit-0013","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1523\/JNEUROSCI.5836-10.2011","article-title":"Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety","volume":"31","author":"Richardson-Jones","year":"2011","journal-title":"J Neurosci"},{"key":"10.1111\/ijcp.12328-BIB0014|ijcp12328-cit-0014","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.neuropharm.2011.02.009","article-title":"Characterization of 5-HT(1A\/1B)-\/- mice: an animal model sensitive to anxiolytic treatments","volume":"61","author":"Guilloux","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1111\/ijcp.12328-BIB0015|ijcp12328-cit-0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0014-2999(92)90142-Q","article-title":"The interaction of R(+)- and S(-)-zacopride with PCPA to modify rodent aversive behaviour","volume":"218","author":"Barnes","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/ijcp.12328-BIB0016|ijcp12328-cit-0016","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(02)02960-6","article-title":"Targeted gene deletion of the 5-HT3A receptor subunit produces an anxiolytic phenotype in mice","volume":"461","author":"Kelley","year":"2003","journal-title":"Eur J Pharmacol"},{"key":"10.1111\/ijcp.12328-BIB0017|ijcp12328-cit-0017","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.bbr.2004.01.018","article-title":"Deletion of the 5-HT3 receptor differentially affects behavior of males and females in the Porsolt forced swim and defensive withdrawal tests","volume":"153","author":"Bhatnagar","year":"2004","journal-title":"Behav Brain Res"},{"key":"10.1111\/ijcp.12328-BIB0018|ijcp12328-cit-0018","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1021\/jm101459g","article-title":"Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder","volume":"54","author":"Bang-Andersen","year":"2011","journal-title":"J Med Chem"},{"key":"10.1111\/ijcp.12328-BIB0019|ijcp12328-cit-0019","first-page":"47","article-title":"In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets","volume":"16","author":"Westrich","year":"2012","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1111\/ijcp.12328-BIB0020|ijcp12328-cit-0020","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1124\/jpet.111.189068","article-title":"Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder","volume":"340","author":"Mork","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/ijcp.12328-BIB0021|ijcp12328-cit-0021","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.euroneuro.2012.04.006","article-title":"Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study","volume":"23","author":"Pehrson","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0022|ijcp12328-cit-0022","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1017\/S1461145711001027","article-title":"A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder","volume":"15","author":"Alvarez","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0023|ijcp12328-cit-0023","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.euroneuro.2011.11.008","article-title":"A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)","volume":"22","author":"Baldwin","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0024|ijcp12328-cit-0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1176\/appi.ajp.2008.08020247","article-title":"Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder","volume":"166","author":"Bridge","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0025|ijcp12328-cit-0025","doi-asserted-by":"crossref","first-page":"953","DOI":"10.4088\/JCP.11m07470","article-title":"A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder","volume":"73","author":"Henigsberg","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0026|ijcp12328-cit-0026","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/YIC.0b013e3283542457","article-title":"A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder","volume":"27","author":"Katona","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0027|ijcp12328-cit-0027","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1177\/0269881112441866","article-title":"A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder","volume":"26","author":"Boulenger","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0028|ijcp12328-cit-0028","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1017\/S1461145712000727","article-title":"A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5\u00a0mg vortioxetine in adults with major depressive disorder","volume":"16","author":"Jain","year":"2013","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0029|ijcp12328-cit-0029","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.euroneuro.2012.07.011","article-title":"Vortioxetine (Lu AA21004) 5\u00a0mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States","volume":"22","author":"Rothschild","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0030|ijcp12328-cit-0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.euroneuro.2012.07.012","article-title":"Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial","volume":"22","author":"Bidzan","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0031|ijcp12328-cit-0031","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/YIC.0b013e3283530ad7","article-title":"Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder","volume":"27","author":"Baldwin","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0032|ijcp12328-cit-0032","first-page":"427","volume-title":"Anxiety Disorder. Diagnostic & Statistics Manual - 4th Edition","author":"American Psychiatric Association","year":"2000","edition":"4"},{"key":"10.1111\/ijcp.12328-BIB0033|ijcp12328-cit-0033","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0034|ijcp12328-cit-0034","first-page":"217","volume-title":"Clinical Global Impressions (028-CGI)","author":"Guy","year":"1976"},{"key":"10.1111\/ijcp.12328-BIB0035|ijcp12328-cit-0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The Hospital Anxiety and Depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1111\/ijcp.12328-BIB0036|ijcp12328-cit-0036","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0037|ijcp12328-cit-0037","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/009262300278623","article-title":"The Arizona Sexual Experience Scale (ASEX): reliability and validity","volume":"26","author":"McGahuey","year":"2000","journal-title":"J Sex Marital Ther"},{"key":"10.1111\/ijcp.12328-BIB0038|ijcp12328-cit-0038","doi-asserted-by":"crossref","first-page":"686","DOI":"10.4088\/JCP.v66n0603","article-title":"Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder","volume":"66","author":"Delgado","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0039|ijcp12328-cit-0039","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4088\/JCP.10m06191","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0040|ijcp12328-cit-0040","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1017\/S1461145702002912","article-title":"Are placebo controls necessary to test new antidepressants and anxiolytics?","volume":"5","author":"Khan","year":"2002","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0041|ijcp12328-cit-0041","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/0269881107076996","article-title":"An effect-size analysis of pharmacologic treatments for generalized anxiety disorder","volume":"21","author":"Hidalgo","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0042|ijcp12328-cit-0042","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","article-title":"Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response","volume":"30","author":"Kobak","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0043|ijcp12328-cit-0043","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0044|ijcp12328-cit-0044","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4088\/PCC.v10n0405","article-title":"Major depressive disorder, obsessive-compulsive disorder, and generalized anxiety disorder: do the sexual dysfunctions differ?","volume":"10","author":"Kendurkar","year":"2008","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"10.1111\/ijcp.12328-BIB0045|ijcp12328-cit-0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","article-title":"Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial","volume":"22","author":"Hartford","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1111\/ijcp.12328-BIB0046|ijcp12328-cit-0046","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4088\/PCC.v09n0203","article-title":"Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians","volume":"9","author":"Koponen","year":"2007","journal-title":"Prim Care Companion J Clin Psychiatry"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijcp.12328","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:07:40Z","timestamp":1643350060000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.12328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,17]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"URL":"https:\/\/doi.org\/10.1111\/ijcp.12328","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,17]]},"assertion":[{"value":"2013-12-17","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}